Piramal Pharma (NSE:PPLPHARMA) Total Equity: ₹81,626 Mil (As of Mar. 2026)


NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
51 GF Score
Price ₹177.16
GF Value ₹174.61
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Piramal Pharma Total Equity?

Piramal Pharma NSE:PPLPHARMA +3.01% 51 Total Equity is ₹81,626 Mil as of Mar. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 51/100 and a GF Value™ of ₹174.61 (Fairly Valued). The stock has 4 warning signs investors should review.

Piramal Pharma's total equity for the quarter that ended in Mar. 2026 was ₹81,626 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Piramal Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Total Equity Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial 66,966.00 67,735.00 79,113.70 81,254.70 81,626.20

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81,254.70 0.00 80,737.90 0.00 81,626.20
NSE:PPLPHARMA
51GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Piramal Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Piramal Pharma's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=179650.4-98024.2
=81,626

Piramal Pharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=179650.4-98024.2
=81,626

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹81,626 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Total Equity of ₹81,626 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Piramal Pharma and its competitors.
Is Piramal Pharma's Total Equity too high?
Piramal Pharma's current Total Equity is ₹81,626 Mil. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Total Equity compare to ZTS and UTHR?
Piramal Pharma's Total Equity of ₹81,626 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Piramal Pharma and its competitors. Piramal Pharma's current Total Equity is ₹81,626 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹174.61, compared to a current price of ₹177.16 — trading 1.5% above its estimated fair value. The current Total Equity is ₹81,626 Mil. Piramal Pharma's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Total Equity is ₹81,626 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued. The current stock price of ₹177.16 is trading 1.5% above its estimated GF Value™ of ₹174.61. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Total Equity: ₹81,626 Mil
  • GF Value™: ₹174.61 vs. price of ₹177.16 (1.5% above fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score

Get the complete analysis for NSE:PPLPHARMA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹177.16
Price
₹174.61
GF Value